CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
37.24
-0.64 (-1.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close37.88
Open38.09
Bid36.50 x 1100
Ask37.84 x 1800
Day's Range36.72 - 38.25
52 Week Range22.22 - 73.90
Volume545,900
Avg. Volume893,826
Market Cap1.947B
Beta (3Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-3.44
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.94
Trade prices are not sourced from all markets
  • 5 Top Gene-Editing Stocks for 2019
    Motley Fool13 days ago

    5 Top Gene-Editing Stocks for 2019

    The future of treating disease might be gene editing, and these five stocks have the most promising technologies.

  • Has CRISPR Therapeutics AG (NASDAQ:CRSP) Got Enough Cash?
    Simply Wall St.13 days ago

    Has CRISPR Therapeutics AG (NASDAQ:CRSP) Got Enough Cash?

    Stocks with market capitalization between $2B and $10B, such as CRISPR Therapeutics AG (NASDAQ:CRSP) with a size of US$2.0b, do not attract as much attention from the investing community asRead More...

  • GlobeNewswire14 days ago

    CRISPR Therapeutics to Participate in Upcoming Investor Conferences

    ZUG, Switzerland and CAMBRIDGE, Mass., March 06, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.

  • Why NOW Is the Time to Buy Gene Therapy Stocks
    InvestorPlace16 days ago

    Why NOW Is the Time to Buy Gene Therapy Stocks

    The biotech industry has been on a tear in 2019, up 25% through the first two months of the year. That's great. But niche gene therapy stocks are performing even better.Source: Shutterstock The rally has been fueled by a strong combination of merger announcements, positive news from the FDA and the continued development of breakthrough therapies. Headlines have been popping up nonstop over the last week, and today I'd like to recap some of the highlights. Spark Therapeutics (NASDAQ:ONCE), a small-cap biotech that focuses on gene therapies, was purchased by pharmaceutical giant Roche (OTCMKTS:RHHBY). On a per-share basis, the $4.8 billion purchase price equated to $114.50 -- a huge 122% premium over ONCE's previous close. Spark investors are now looking at 190% gains in 2019 alone.The same day, CRISPR Therapeutics (NASDAQ:CRSP) announced that human trials had begun for its CTX001 gene therapy drug. A patient suffering from beta-thalassemia had been dosed. And in just a few months, the same drug is expected to be tested on patients with sickle cell disease.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCTX001, which is based on the CRISPR/Cas9 gene editing technique, is currently undergoing Phase I/II trials. Typically, the first dose in such a trial would not be a headline. But this was the first time that CRISPR technology had ever been used on a human. The news sent CRSP up more than 20%. * 7 Top-Rated Stocks to Buy for March A few days later, gene therapy stock Sarepta Therapeutics (NASDAQ:SRPT) released impressive results for its muscular dystrophy drug. And in the same press release it announced the $165 million purchase of privately-held gene therapy company Myonexus. The stock rallied on the news and is now up 34% so far this year. But even with the acquisition news, SRPT has long been rumored as a takeover target for larger pharmaceutical companies.Finally, micro-cap gene therapy stock MeiraGTx Holdings (NASDAQ:MGTX) announced an $80 million private placement. This is important because its lead investor is the private arm of Johnson & Johnson (NYSE:JNJ). MeiraGTx is already up a whopping 67% in 2019. Get in Position for Life-Changing Profits from Gene Therapy StocksThere is absolutely no question that there is money to be made in the gene therapy stocks over the long term. However, because the sector is still in its infancy, we have to expect increased volatility. What we're seeing now is a very strong upswing.Gene therapy is on track to save countless lives. It's also on track to make you life-changing profits as long as you can weather the ups and downs that are simply the nature of early-stage mega-trends.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever Compare Brokers The post Why NOW Is the Time to Buy Gene Therapy Stocks appeared first on InvestorPlace.

  • Zacks16 days ago

    S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks

    S&P; Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks

  • GlobeNewswire21 days ago

    CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

    ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.

  • CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again
    InvestorPlace21 days ago

    CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again

    Although CRISPR Therapeutics (NASDAQ: CRSP) reported negligible revenue and a loss for the fourth quarter on Monday, the owners of CRSP stock are taking the results in stride.The value of the company is in its gene-editing technology, which is a huge advancement in health sciences. From an investing point of view, CRSP is not going to make any revenue, let alone profits, for the foreseeable future. CRSP stock rallied about 25% on Monday after Roche (OTCQX: RHHBY) agreed to buy CRSP's competitor, Spark Therapeutics (NASDAQ: ONCE) * 7 IPOs to Get Excited for in 2019 Spark Bought OutRoche offered to buy Spark for $114.50 per share in cash for a total price tag of $4.8 billion. This offer is more than double the price at which Spark closed on Friday. The buyout is irrational from a financial point of view because Spark's losses have mounted, according to its latest financial report. Although its revenue rose about 400% to $64.73 million in Q4, it lost $2.11 a share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock With that backdrop in mind, CRSP's losses in the quarter will not worry the owners of CRSP stock because, in the wake of the Roche-Spark deal, they will believe that CRSP could also get acquired. So instead of focusing on the company's financial results, the market may turn its focus to the clinical achievements the firm made in 2018. 2018 HighlightsCRSP, along with its partner Vertex (NASDAQ:VRTX), continued to advance a number of its key programs in 2018. Among the diseases the companies are looking to treat are β-thalassemia, "a blood disorder that reduces the production of hemoglobin," according to the NIH, and sickle cell disease (SCD). CRSP and VRTX are also working on immuno-oncology.In the area of hemoglobin disorders, including β-thalassemia and sickle cell disease, CRISPR treated a patient with its CTX001 , a gene-edited stem cell therapy, for the first time, the company announced on Monday.The patient was treated during a Phase 1/2 study of CTX001 in patients with transfusion-dependent beta thalassemia. At the same time, the companies said they have launched a Phase 1/II trial of patients with severe SCD, and they noted that the first patient with the disease is expected to be infused with CTX001 in the middle of this year. All of the patients participating in both trials will have their own edited hematopoietic stem cells injected into them."Patients will initially be monitored to determine when the edited cells begin to produce mature blood cells, a process known as engraftment," the companies stated.In the area of Immuno-Oncology, CRISPR will start a trial of CTX110, a CAR-T cell therapy, in the first half of 2019. The company will use its gene-editing technique to target blood cancers that arise from B cells. It is worth noting that a preclinical study of CTX120, CRISPR's CAR-T cell therapy for the treatment of multiple myeloma, showed durable cytotoxic capacity.. These results gave the company the positive data it needs to continue its study in patients. Balance Sheet AnalysisInvestors absolutely must review at least the cash position of emerging biotechnology companies. Worth noting when evaluating CRISPR is that its healthy cash and cash equivalents of $456.6 million may mean the company will not need to sell stock to raise cash this year.In Q4, the company spent $28.8 million on R&D, up from $20 million last year. Its R&D spending could increase, depending on the progress of CRISPRs clinical studies. The Valuation of CRSP StockInvestors may only guess what CRSP stock is worth. The addressable market that the company is targeting is very large Using a 10-year DCF Revenue Exit model, if the company's revenue jumps 25% - 100%, CRSP stock is worth over $40 a share.Seven analysts who cover CRSP stock have an average price target that is over 40% above its recent price of around $37, according to Tipranks.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again appeared first on InvestorPlace.

  • Biotech ETFs Jump on Roche-Spark Deal
    Zacks22 days ago

    Biotech ETFs Jump on Roche-Spark Deal

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

  • CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
    Zacks22 days ago

    CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

    CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.

  • Zacks22 days ago

    Deal on the Way Now that Deadline is Delayed?

    Deal on the Way Now that Deadline is Delayed?

  • Why Danaher, CRISPR Therapeutics, and Clementia Pharmaceuticals Jumped Today
    Motley Fool23 days ago

    Why Danaher, CRISPR Therapeutics, and Clementia Pharmaceuticals Jumped Today

    A big day in biotech helped lift the market.

  • Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient
    Investor's Business Daily23 days ago

    Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient

    Crispr Therapeutics stock popped Monday after the biotech announced it dosed a patient with its gene-editing therapy — making it the first firm to use CRISPR technology in a clinical study.

  • Here's Why Gene Therapy Stocks Are Soaring Today
    Motley Fool23 days ago

    Here's Why Gene Therapy Stocks Are Soaring Today

    Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.

  • Crispr Infuses First Human in Landmark Gene-Editing Study
    Bloomberg23 days ago

    Crispr Infuses First Human in Landmark Gene-Editing Study

    Crispr Therapeutics and partner Vertex Pharmaceuticals Inc. said on Monday morning that the first patient in a trial using CTX001, a therapy created using Crispr technology, as a treatment for the rare blood disease, beta thalassemia, received the one-time medicine. The pair also announced the enrollment of the first patient has started in a parallel study for the medicine in sickle-cell disease with the first dosing on track for mid-year. “Treating the first patient in this study marks an important scientific and medical milestone and the beginning of our efforts to fully realize the promise of CRISPR/Cas9 therapies as a new class of potentially transformative medicines to treat serious diseases,” Samarth Kulkarni, Chief Executive Officer of Crispr Therapeutics, said in a statement.

  • GlobeNewswire23 days ago

    CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018. “This past year was truly transformational for CRISPR Therapeutics as we achieved milestones across our key programs in β-thalassemia, sickle cell disease and immuno-oncology. This progress brings us closer to realizing our mission of bringing transformative therapies to patients with serious diseases,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.

  • GlobeNewswire23 days ago

    CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

    CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies. The companies announced that the first patient has been treated with CTX001 in a Phase 1/2 clinical study of patients with transfusion-dependent beta thalassemia (TDT), marking the first company-sponsored use of a CRISPR/Cas9 therapy in a clinical trial.

  • Zacks25 days ago

    Strong Friday Close Secures a 9th Week in the Green

    Strong Friday Close Secures a 9th Week in the Green

  • GlobeNewswire27 days ago

    CRISPR Therapeutics Proposes New Members to the Board of Directors

    CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect John T. Greene and Katherine A. High, M.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year. “We are very pleased to invite John and Kathy to join our Board of Directors. Together, they will bring significant strategic and operational experience to CRISPR Therapeutics during a critical stage of our company’s growth,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.

  • GlobeNewswire29 days ago

    CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

    ZUG, Switzerland and CAMBRIDGE, Mass. and Durham, N.C., Feb. 19, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative.

  • Is Moderna a Buy?
    Motley Foollast month

    Is Moderna a Buy?

    The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.

  • Benzingalast month

    Jim Cramer Gives His Opinion On Cronos, Etsy And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said Cronos Group Inc (NASDAQ: CRON ) is at the top of the range. He would take some off the table on Tuesday. Manitowoc Company Inc (NYSE: ...

  • Here's Why CRISPR Therapeutics Rose 13.5% in January
    Motley Foollast month

    Here's Why CRISPR Therapeutics Rose 13.5% in January

    The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.

  • Should Sangamo's Failure Make CRISPR Investors Nervous?
    Motley Foollast month

    Should Sangamo's Failure Make CRISPR Investors Nervous?

    The latest gene therapy to flop in a clinical trial pulled CRISPR stocks down with it.

  • Vertex Pharmaceuticals: New Drug, Same Great Growth Story
    Motley Foollast month

    Vertex Pharmaceuticals: New Drug, Same Great Growth Story

    The biotech continues to make inroads in cystic fibrosis.